Drug Profile
Efinopegdutide - Hanmi Pharmaceutical
Alternative Names: GLP-1/glucagon-agonist; Glucagon-like-peptides/glucagon; Glucagon/GLP-1-agonist; HM-12525A; JNJ 5111; JNJ-64565111; LAPS GLP/GCG; LAPS-GCG/GLP-1; LAPS-GLP-1/GCG; LAPS-GLP/Glucagon; LAPS-OXM; MK-6024; Oxyntomodulin immunoglobulin conjugateLatest Information Update: 27 Nov 2023
Price :
$50
*
At a glance
- Originator Hanmi Pharmaceutical
- Developer Hanmi Pharmaceutical; Janssen Pharmaceuticals; Merck & Co
- Class Antihyperglycaemics; Gastrointestinal hormones; Glucagon-like peptides; Obesity therapies; Recombinant fusion proteins
- Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Non-alcoholic steatohepatitis
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 22 Nov 2023 Merck Sharp & Dohme initiates a phase I pharmacokinetic trial in Healthy volunteers and participants with Hepatic impairment in USA (SC) (NCT06052566)
- 10 Nov 2023 Updated efficacy data from a phase IIa MK-6024-001 trial in Non-alcoholic steatohepatitis presented at the 74th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2023)
- 25 Sep 2023 Merck Sharp & Dohme plans a phase I trial in healthy participants and in participants with hepatic impairement (SC, Injection) in October 2023 (NCT06052566)